Abbott receives FDA approval for generic version of iopamidol

Article

Abbott could drive contrast prices even lowerPrices for x-ray contrast media in the U.S. could go even lower in the next several months after healthcare giant Abbott Laboratories introduces its generic version of iopamidol. The Food and Drug

Abbott could drive contrast prices even lower

Prices for x-ray contrast media in the U.S. could go even lower in the next several months after healthcare giant Abbott Laboratories introduces its generic version of iopamidol. The Food and Drug Administration ruled in December that a version of iopamidol developed by the Abbott Park, IL, company is the generic equivalent of Isovue, a nonionic, low-osmolar x-ray contrast agent developed by Bracco of Milan, Italy.

The expiration of Bracco's U.S. patents on iopamidol has prompted consternation among established contrast agent companies like Bracco, Nycomed, and Mallinckrodt, because generic versions of iopamidol will compete with low-osmolar nonionic products from all companies. The arrival of generic iopamidol is believed to be one of the factors behind the ongoing slump in prices for contrast agents, and the drop has prompted several contrast companies to seek mergers with other firms to reduce their reliance on the x-ray market.

Abbott is only one of several companies developing generic versions of iopamidol, with other potential competitors including ESI-Lederle, Hovione of Portugal, Faulding Pharmaceutical, and Brightstone Pharma. Faulding received FDA approval for its version of iopamidol in 1996 (SCAN 12/18/96).

Abbott's introduction of iopamidol could have the biggest impact on the market, however, due to the company's extensive distribution network. Abbott's small army of field sales representatives are already calling on hospitals regarding other products, and it should be relatively easy for the company to insert generic iopamidol into its product offerings. The company is planning to begin selling the product some time this spring, an Abbott spokesperson said.

Iopamidol will also round out Abbott's expanding product portfolio. The company already offers MRI and x-ray contrast agents it has accessed through an agreement signed in 1996 with Schering subsidiary Berlex Laboratories (SCAN 7/3/96). Abbott also has rights to EchoGen, an ultrasound contrast agent under development by Sonus Pharmaceuticals that is expected to be close to FDA approval.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.